Panvax(®): a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009.

Abstract

Panvax(®) (CSL Biotherapies, Parkville, Australia) is one of a number of pandemic influenza A (H1N1) 2009 (pH1N1) vaccines fast-tracked for production, clinical trials and licensure in response to the emergence of the novel pH1N1 strain in early-mid-2009. Unexpectedly good immunogenicity following a single 15-µg dose was demonstrated in expedited clinical trials in adults and children. This facilitated early licensure and then rapid rollout for population immunization from October 2009. The vaccine's safety profile in the Australian population has been excellent.

• Authors: Jodie McVernon, Terry Nolan
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 10 Issue 1 Pg. 35-43 (Jan 2011) ISSN: 1744-8395 [Electronic] England
• PMID: 21162618 (Publication Type: Journal Article, Review)

Chemical References

• Influenza Vaccines
• panvax

Topics

• Clinical Trials as Topic
• Drug Approval
• Humans
• Influenza A Virus, H1N1 Subtype (immunology)
• Influenza Vaccines (adverse effects, immunology)
• Influenza, Human (prevention & control, virology)